Search clinical trials for: PF-07104091 + PF-07220060 + fulvestrant dose expansion

Total 86 results

Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa, Mexico
Pfizer

Recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

China, United States, Japan, Mexico
Pfizer

Active, not recruiting

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
Pfizer

Recruiting

A Study for Two Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Breast Cancer

United States, Japan, Puerto Rico
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Olatec Therapeutics LLC

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Arthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout Attack

United States, Spain, France
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, United Kingdom, Poland, Germany
Pfizer

Terminated

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Parkinson Disease

United States, France, Israel, Germany
Mahidol University
Clinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...

Completed

Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine

COVID-19 Infection | COVID-19 VACCINE

Thailand
Scripps Poway Eyecare and Optometry
Sengi

Recruiting

Subjective and Objective Performance of Systane Complete Multi-Dose PF Versus Walgreen's Lubricant Balance

Dry Eye

United States
Pfizer

Recruiting

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Shingles | Human | Herpes Zoster Infection

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Israel, Taiwan, Argentina, Japan, Korea, Republic of, Canada, Australia, Brazil
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

Advanced Breast Cancer

China, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
Chuangzhen Chen

Active, not recruiting

Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer (SUMC-EC-002)

Esophageal Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Healthy

United States
Pfizer

Withdrawn

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Liposarcoma | Endometrial
Pfizer

Completed

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Pfizer

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Breast Neoplasms | Prostate Cancer | Adenocarcinoma of Lung | Solid Tumors | Liposarcoma | CRC

China, United States, United Kingdom, Mexico, Czechia, Japan, Slovakia, Argentina
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Washington University School of Medicine
United States Department of Defense; Puma Biotechnology, Inc.

Completed

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Breast Neoplasms

United States, Canada
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
University of Florida

Completed

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

Glaucoma

United States
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Hoffman Oncology
DSCS CRO

Active, not recruiting

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Breast Cancer

United States
Pfizer

Completed

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Acute Myeloid Leukemia

Japan
Pfizer

Completed

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia

United States, Spain, Germany, Italy, Poland, Canada
Children's Hospital of Philadelphia
Gateway for Cancer Research

Completed

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Osteosarcoma | Nephrotoxicity | Ototoxicity

United States
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 | Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8

United States

Search clinical trials for: PF-07104091 + PF-07220060 + fulvestrant dose expansion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations